LAKSHMI PRASANTHI NORI

Dr. LAKSHMI PRASANTHI NORI


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2023 in BioTech
Verified
Journal Article
Open access
PDF file
JLJada Naga Lakshmi
Jada Naga Lakshmi
ABAnkem Narendra Babu
Ankem Narendra Babu
SKS. S. Mani Kiran
S. S. Mani Kiran
LNLAKSHMI PRASANTHI NORI
LAKSHMI PRASANTHI NORI
NHNageeb A.G.M. Hassan
Nageeb A.G.M. Hassan
ASAfzal Shaik
Afzal Shaik
Background: Polycystic ovarian syndrome (PCOS) is a neuroendocrine metabolic disorder characterized by an irregular menstrual cycle. Treatment for PCOS using synthetic drugs is effective. However, PCOS patients are attracted towards natural remedies due to the effective therapeutic outcomes with natural drugs and the limitations of allopathic medicines. In view of the significance of herbal remedies, herein, we discuss the role of different herbs in PCOS. Methods: By referring to the Scopus, PubMed, Google Scholar, Crossref and Hinari databases, a thorough literature search was conducted and data mining was performed pertaining to the effectiveness of herbal remedies against PCOS. Results: In this review, we discuss the significance of herbal remedies in the treatment of PCOS, and the chemical composition, mechanism of action and therapeutic application of selected herbal drugs against PCOS. Conclusions: The present review will be an excellent resource for researchers working on understanding the role of herbal medicine in PCOS.

12 February 2025 in International Journal of Pharmaceutical Investigation
Verified
Journal Article
Open access
PDF file
LNLAKSHMI PRASANTHI NORI
LAKSHMI PRASANTHI NORI
MLMaddala Lohitha
Maddala Lohitha
RVRama Rao Vadapalli
Rama Rao Vadapalli
BBBrahmaiah Bonthagarala
Brahmaiah Bonthagarala
SNSudarshan Rao Nagineni
Sudarshan Rao Nagineni
KRK. VENKATESWARA RAJU
K. VENKATESWARA RAJU
Artificial Intelligence (AI) is ushering in a transformative era for personalized medicine by customizing therapeutic interventions based on individual patient profiles, including genetic information and environmental influences. Through the analysis of intricate biological datasets, AI significantly improves diagnostic accuracy, prognostic assessments and therapeutic planning, thereby enabling more precise patient stratification and enhanced clinical outcomes. This advancement is particularly evident in the realms of genomic analysis and pharmacogenomics. Nonetheless, the integration of AI into healthcare introduces substantial legal and ethical considerations. Foremost among these are concerns related to data privacy, security and equitable access to treatment. It is imperative to address these issues to effectively leverage the full potential of AI. Achieving this requires a reevaluation of regulatory frameworks and an enhancement of training programs for healthcare professionals. As AI continues to advance within the healthcare sector, it promises to fundamentally redefine disease management and prevention, heralding a new epoch of medical innovation.

1 January 2024 in Brazilian Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
KRK. VENKATESWARA RAJU
K. VENKATESWARA RAJU
SRSheik Rehana
Sheik Rehana
SSSarvan Manikiran Seethamraju
Sarvan Manikiran Seethamraju
LNLAKSHMI PRASANTHI NORI
LAKSHMI PRASANTHI NORI
In the biopharmaceutical industry, the conventional “linear and sequential” clinical trial approach is still the norm; however, it is frequently beset by issues with patient selection, retention, and monitoring that are not up to par, leading to longer trial durations and higher trial failure rates. Artificial intelligence (AI) has the potential to reduce the duration of clinical trials significantly, expedite protocol design and study implementation, improve trial outcomes, and lower the cost of biopharmaceutical R&D. AI may also speed up clinical cycle times. Clinical trial mining, design and execution, and real-world experience analysis are all possible using AI. Major drug makers are utilizing AI to locate volunteers for clinical trials or to cut down on the number of subjects required for drug testing, which might speed up medication development and save millions of dollars. The clinical trial procedure may be enhanced by AI, but evidentiary requirements for a drug’s efficacy and safety won’t alter, according to regulators. This article discusses the application of AI, RWD, and RWE in clinical trials and how it is transforming the biopharma value chain, encompassing all pharmaceutical firms referred to as “biopharma companies” due to the inclusion of biologics in their development pipelines and within these biopharma firms, artificial intelligence (AI) is finding its way into drug research.

4 October 2024 in Indian Journal of Pharmaceutical Education and Research
Verified
Journal Article
Open access
PDF file
VKVenkateswara Raju Kalidindi
Venkateswara Raju Kalidindi
BDBandaru Mani Sai Durga
Bandaru Mani Sai Durga
LNLAKSHMI PRASANTHI NORI
LAKSHMI PRASANTHI NORI
The process of officially calling something back to its original or initial location is termed as “recall.” Pharmaceutical recalls involve requesting to get back a product after it leaves the manufacturer to reach the distributor, retailer, or consumer. In place of the discovery of defect that affects the quality safety and efficacy of the product. Drug product recalls occur due to various reasons such as wrong or unapproved drugs, undeclared ingredients, contamination, incorrect information, and particulate issues. The probable risks or issues that arise due to a product recall or claims related to product liability and legal issues. A product recall should be perceived as an opportunity for the elimination of personal injury to the patient and damage to the reputation of the company products and rebuilding trust. Quality culture across the organization is a means of product recall prevention. In this comprehensive analysis, we delve into the drug recall statistics spanning the fiscal year 2018 to 2023 (up to July), focusing on the distinct challenges posed by recalls attributed to a lack of sterility assurance and those due to impurity profiles. Unveiling critical insights, the study highlights the impact of these issues on the pharmaceutical industry’s commitment to ensuring the safety and quality of drug products. This unique analysis presents a call to action for collaborative efforts between regulatory authorities, manufacturers, and healthcare professionals. Emphasizing the value of transparent communication and proactive measures, we explore avenues to mitigate recalls and reinforce public trust in pharmaceutical products. By drawing insights from past incidents, the industry can forge a path towards a safer, more reliable future, where drug recalls due to sterility and impurity issues become rare occurrences. Swift and thorough recalls are vital to ensure patient safety. The rising trend in recalls, caused by company discovery, customer complaints, or FDA observations, impacts sales, customer relations, and supply chains. Recalls involve planned actions, including depth of recall, public alerts, and effectiveness checks.

1 January 2024 in Pharmacophore
Verified
Journal Article
Open access
PDF file
SSSarvan Manikiran Seethamraju
Sarvan Manikiran Seethamraju
LNLAKSHMI PRASANTHI NORI
LAKSHMI PRASANTHI NORI
It is a challenging task to administer the appropriate quantities of drugs to the eye mainly to the retina. Retinal transmission is urgently required due to potential vision loss caused by retinal disease. The failure to provide retinal transmission of topical or systemic routes is now widely accepted. The intravitreal path offers a high regional density of drugs which induces cataracts, retinal detachment, and endophthalmitis. Periocular route utilizing the sclera's permeability for the tra

18 November 2024 in Indian Journal of Pharmaceutical Education and Research
Verified
Journal Article
Open access
PDF file
VKVenkateswara Raju Kalidindi
Venkateswara Raju Kalidindi
SRShankar Routhu
Shankar Routhu
DGDhamasri Gopisetty
Dhamasri Gopisetty
PAPhanindra Varma Alluri
Phanindra Varma Alluri
LNLAKSHMI PRASANTHI NORI
LAKSHMI PRASANTHI NORI
Dietary supplements generally items which have the goal of boosting the person's wellness and general well-being and are often ingested at mealtime or in scheduled times in order to improve a person's dietary routine. Once an individual has a nutritional unbalance or as a shortage of certain nutrients, supplementation needs to be taken. Classes of dietary supplements include Vitamins, Minerals, Proteins, Multivitamins, Multiminerals, Herbs, Carbohydrates, hormone activators and oil supplements are present in the form of pill, tablets, capsules and liquids. Supplements should enable individuals having limited nutritional consumption along with effectiveness and also have higher requirements, via strengthening nutrition significance. The risk associated with food supplements, toxicity of the supplements, market trends and future perspectives were also presented. Some include the technical as well as legislative obstacles currently encountered within supplements effectiveness, safety and quality studies. For each country there are separate regulatory approval frameworks and also labelling requirements for the import and export of the food product. So, dietary supplements play a crucial role in every individual.